RB-312
/ Refuge Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 02, 2023
Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment.
(PubMed, J Transl Med)
- "RB-312, the first clinically relevant product incorporating a CRISPRa system with non-gene editing and reversible upregulation of endogenous gene expression that promotes CAR-T cells persistence and effectiveness against HER2-expressing tumors. The autocrine effects of reversible, nanoscale IL-12 production limits the risk of off-tumor leakage and systemic toxicity."
CAR T-Cell Therapy • IO biomarker • Journal • Head and Neck Cancer • Hematological Disorders • Hematological Malignancies • Immune Modulation • Oncology • Oropharyngeal Cancer • Solid Tumor • IL12A • RELA
1 to 1
Of
1
Go to page
1